|Send to printer »|
Corporate Profiles : Apr 15, 2007 ( )
SynCo Bio Partners Is Poised for Expansion
CMO Focused Exclusively on Development and Manufacturing of Biopharmaceuticals!--h2>
Although there are numerous contract manufacturing organizations (CMOs) for small molecule drugs worldwide, few CMOs make biopharmaceuticals. At SynCo Bio Partners (www.syncobio.com), based in Amsterdam, the focus is entirely on the development and manufacturing of biopharmaceuticals in small quantities for clinical trials and larger amounts for commercial products. The company’s clients range from large international pharmaceutical houses to biotechnology startups.
This GMP contract manufacturer offers a range of services, including process development of early clinical trial supplies and the manufacturing of licensed products. SynCo Bio Partners has produced conjugated vaccines, polysaccharides, live attenuated vaccines, and recombinant proteins generated in microbial and mammalian cells. In addition, the company provides aseptic liquid filling and lyophilization services.
Acquisition from Chiron
SynCo was founded in 2000 and acquired the Amsterdam manufacturing facility from Chiron. The founding teams’ experience in process development and GMP manufacturing was gained from working in that facility under Chiron management. This expertise provided the foundations for SynCo’s future growth. A second GMP unit was built on the site in 2005, and the company improved its fill-and-finish suite the same year. Over the years, the staff has grown from 35 in 2000 to 115 today.
“In addition to our experience in conventional systems, such as E. coli and CHO cells, we have expertise in areas that are essential in the production of vaccines,” says Andrew Lewin, director of business development.
For example, all of SynCo’s GMP areas are rated as BioSafety Level 2. “For general manufacturing of products in E. coli or mammalian cells, you don’t need that level of safety,” says Lewin, but “in vaccine production, specific expertise and facilities to allow the cultivation of pathogenic bacteria and the manufacture of products containing live organisms is required. This explains our ability to offer services suitable for vaccine production and our continued success in what we see as a quickly expanding market.”
“When SynCo was first established, we were mainly producing material for Phase III trials and the commercial market in our existing 1,500-L microbial fermentation-scale GMP facility,” says Joanne McCudden, business development manager. In order to grow the business, SynCo Bio Partners expanded its process and analytical development services to produce biopharmaceuticals for early-phase clinical trials, which require much smaller amounts of material. The new 5,000-sq-ft GMP facility, licensed by the EMEA in 2006, offers 300-L-scale microbial production or 200-L-scale mammalian cell batch or continuous production in wave bioreactors.
For microbial expression of recombinant proteins, SynCo has facilities with 100–1,500-L fermentation volumes, as well as smaller scale process development. Biosafety Level-2 laboratories allow vaccines and biodefense agents to be produced. For expression in Chinese hamster ovary cells and other mammalian cell lines, a stirred tank GMP bioreactor of 100 L and disposable bioreactors of 200 L generate harvest rates of up to 6,000 liters per month.
Four distinct downstream processing suites perform standard filtration, ultrafiltration, column chromatography, and preparative-scale HPLC. The fill-and-finish service can process up to 20,000 vials per batch, including aseptic filling and freeze drying of biopharmaceuticals for both clinical trials and market supply.
SynCo places key importance on project management. A program of process development and manufacturing can eventually involve around 100 different people, many of whom play backstage roles, but all who must understand the project goals and deliverables. SynCo has established a formal gated approach to project management, which aims to break the complexity of the overall manufacturing project into easily manageable pieces.
“We have an integrated service that can take clients from the early preclinical stage through clinical trials and to market launch. This service includes process development, scale up, and fill and finish of bulk product,” Lewin says.
In October 2006, Cleveland BioLabs, signed an agreement to transfer the technology for its lead product, Protectan CBLB502, to SynCo to produce sufficient amounts for clinical trials and the commercial market. Protectan CBLB502, a radioprotection molecule that has been shown to rescue test animals from radiation injury, could be stockpiled for biodefense purposes. SynCo will work with Cleveland BioLabs to develop the manufacturing process, based on completed pilot studies, and manufacture Protectan CBLB502 under GMP standards for Phase I testing.
As a potential biodefense product, Protectan CBLB502 is on a fast track to market, and the SynCo facility is capable of producing large quantities for stockpiling. “It was incredibly important to Cleveland BioLabs to find someone with existing experience in manufacturing for the market,” says McCudden. Moreover, Cleveland BioLabs “did not want to work with someone who had to share the learning curve with them,” she adds.
Besides Cleveland BioLabs, SynCo serves other customers in the U. S. About three-quarters of the company’s revenues come from U.S. clients, and the rest largely from European companies. Customers are attracted to SynCo Bio Partners because “we are robust, established with a good track record, and we’ve been profitable for the past seven years,” says Lewin. In fact, the company has orders booked for the next four years.
SynCo is looking to expand to other manufacturing locations as a result of its success in attracting new clients, as well as being able to form strong, long-term, and mutually beneficial relationships with existing clients. The details of SynCo’s expansion plans have not yet been finalized but whatever the outcome, “growth is definitely on the agenda,” Lewin says.
© 2013 Genetic Engineering & Biotechnology News, All Rights Reserved